Moderna Surges 90% on Cancer Vaccine Win as Meta Faces Antitrust Trial and Target Beats

The Quick Take

• Moderna shares surge over 90% after successful skin cancer mRNA vaccine Phase 3 trial results
• Meta faces landmark antitrust trial as government presses case on social media market dominance
• Target beats quarterly estimates in sign of US consumer resilience despite high interest rates

Moderna's shares surged more than 90% after the company announced successful Phase 3 clinical trial results for its mRNA-based skin cancer vaccine, developed in partnership with Merck. The trial data confirms the vaccine's efficacy in reducing melanoma recurrence, a landmark result that validates the broader application of mRNA technology beyond infectious disease and opens a new growth chapter for Moderna following the COVID-19 vaccine revenue decline.

In parallel, Meta Platforms faces the opening of a landmark antitrust trial brought by the US government over its alleged dominance of the social media market, with regulators arguing that the company's acquisitions of Instagram and WhatsApp were designed to eliminate competition. The trial is expected to run for several months and carries significant implications for how large platform acquisitions are evaluated under US antitrust law, with potential remedies ranging from divestiture requirements to behavioral restrictions.

Target Corporation added to the positive market sentiment by reporting quarterly results that beat analyst estimates, signaling resilience in US consumer discretionary spending despite the elevated interest rate environment. The results contrast with concerns about high-income consumers trading down and point to effective inventory management and promotional strategies. Combined, the three stories reflect a market that is simultaneously rewarding biotech innovation, scrutinizing tech consolidation, and finding pockets of consumer strength.

Synthesized from 2 sources.